• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMD Serono expands biopharmaceutical R&D facility in Massachusetts

EMD Serono expands biopharmaceutical R&D facility in Massachusetts

May 3, 2016
CenterWatch Staff

EMD Serono, the biopharmaceutical business of Merck, Darmstadt, Germany, in North America, has announced a $12 million investment for the expansion of its R&D facility in Billerica, Massachusetts. The new building will span more than 30,000 square feet and accommodate approximately 120 new and current employees whose focus will be on accelerating innovation in R&D, with a focus on oncology, immuno-oncology and immunology.

“The purpose of this expansion is to advance innovation and knowledge-sharing across our R&D teams, with the goal of accelerating the discovery and development of new therapies for patients in need,” said Luciano Rossetti, M.D., head of Global R&D for Merck, Darmstadt, Germany. “This investment is a reflection of our strengthening footprint in the Boston area and in the U.S. as a leader in biopharma.”

With approximately 2,000 R&D professionals working across four global R&D hubs—Darmstadt, Germany; Boston, U.S.; Tokyo, Japan; and Beijing, China—Merck KGaA, Darmstadt, Germany endeavors to make a meaningful difference in the lives of people with serious medical needs.

“The growth of EMD Serono’s Billerica campus over the past several years and its decision to continue to grow in Massachusetts is a testament to our state’s leadership in biopharmaceutical innovation,” said Robert K. Coughlin, President & CEO of MassBio, the life sciences trade association. “The company’s long-standing investment here ensures that we continue to retain and attract the top scientific minds and that the medical advances that make a real difference in people’s lives occur here in Massachusetts.”

The new two-story, 30,000 square foot building will be an extension of the existing Sagamore Building and will feature amenities including open plan work areas, a central auditorium, and numerous meeting spaces including bleacher seating for spontaneous collaboration and interaction. In addition to seeking LEED certification to complement the Sagamore Building’s Platinum LEED status, EMD Serono will also apply for the WELL Institute certification. The WELL Institute standards measures the human health and wellness of occupants in the building environment. If achieved, EMD Serono would have one of the first projects in the U.S. with that certification distinction.

Construction on the expansion is scheduled to begin in May 2016 with a planned completion date of June 2017. In addition to its R&D facility in Billerica, EMD Serono’s corporate headquarters are located in Rockland, Massachusetts and in total the company has approximately 800 employees across the state.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing